Biomarkers for alzheimer's disease progression

A technology for Alzheimer's disease and disease, applied in biological testing, biomaterial analysis, drug combination, etc., can solve problems that cannot be cured and the etiology is not fully known

Inactive Publication Date: 2009-08-26
NOVARTIS AG
View PDF71 Cites 6 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The causes of AD are not fully known and there is still no cure

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Biomarkers for alzheimer's disease progression
  • Biomarkers for alzheimer's disease progression
  • Biomarkers for alzheimer's disease progression

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0159] Example 1. AFFYMETRIX 100K Genome Scan in Patients from the InDDEx Trial

[0160] [156] Introduction and Overview. The purpose of this example is to describe a genetic association study that identified 25 AD-associated mutations of the invention. Genome-wide analysis for genetic association studies has only become possible in the past two years. The Investigational Study of Delaying a Diagnosis of Alzheimer's Disease Using Exelon (InDDex; ENA713B IA07) clinical trial followed patients with MCI and administered either different doses of Exelon (rivastigmine) or placebo. agent and track its conversion to AD. The trial optionally had a DNA collection component, in which 442 samples were collected.

[0161] [157] To identify genetic variants that drive the conversion of MCI to AD, 420 patient samples from the InDDex (ENA713B IA07) clinical trial were analyzed using Haploview's case-control assay using the Affymetrix 100K gene assay at single loci and putative haplotype b...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

This invention relates generally to the analytical testing of tissue samples in vitro, and more particularly to aspects of genetic polymorphisms associated with the conversion from Mile Cognitive Impairment to dementia, e.g., Alzheimer's Disease (AD). The invention provides AD-associated mutations which are useful in the diagnosis, prognosis or therapeutic treatment of dementia, e.g., Alzheimer's Disease.

Description

technical field [0001] [01] The present invention relates generally to in vitro analytical detection of tissue samples, and more particularly to aspects of genetic polymorphisms for diagnosis, prognosis, or preventive / therapeutic treatment of dementias, such as Alzheimer's disease. Background technique [0002] [02] Traditional approaches to disease diagnosis and treatment are based on clinical data alone or in combination with diagnostic tests. Such traditional practices often result in treatment options that are not optimal for the efficacy of the prescribed drug therapy, or that do not minimize the likelihood of side effects for the individual subject. Therapy-specific diagnostics (aka theranostics) is an emerging field of medical technology that provides useful assays for diagnosing disease, selecting the correct treatment regimen, and monitoring the response of subjects. More precisely, theranostics is useful for predicting and assessing drug response in individual sub...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K45/00A61P25/28
CPCA61K31/222Y10T436/143333A61P25/28A61K45/00G01N33/68
Inventor J·B·辛格
Owner NOVARTIS AG
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap